New 'Off-the-Shelf' cell therapy trial targets six severe autoimmune diseases
NCT ID NCT07301164
Summary
This early-stage study is testing a new cell therapy called BCT301 for people with severe autoimmune diseases that haven't responded to standard treatments. The therapy uses lab-made immune cells designed to target and remove harmful B cells, which are thought to drive these diseases. The main goals are to check the treatment's safety, find the right dose, and see if it helps control the diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.